Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: the ASCERTAIN project
Carin A. Uyl-de Groot, Eline Aas, Kate Morgan(Association des Operateurs Postaux Publics Europeens), Oliver Groene, Robin Doeswijk(European Hematology Association), Anne Hendrickx(International Association of Public Transport), Emily A. Burger, Renaud Heine(Erasmus University Rotterdam), Tomáš Tesař, Frederick W. Thielen(University Medical Center Freiburg), Monica Racoviță, Mauro Melli, Gauthier Quinonez, N Xander(Erasmus University Rotterdam), van Bruggen A, Tom Belleman(Erasmus University Rotterdam), Pia S. Henkel(University of Oslo), Mirjana Huić, Yansi Wu, Isabelle Durand-Zaleski, Maximilian Salcher‐Konrad(London School of Economics and Political Science), Peter Schneider, Benjamin P. Geisler
London School of Economics and Political Science Research Online (London School of Economics and Political Science)
January 1, 2026
Cited by 0
Related Papers
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345
How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3)
|Expert Review of Pharmacoeconomics & Outcomes Research|2016|138
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States
|Milbank Quarterly|2020|87
Generating comparative evidence on new drugs and devices before approval
|The Lancet|2020|80